ATE527355T1 - Halbweiche immunstimulierende oligonukleotide der c-klasse - Google Patents

Halbweiche immunstimulierende oligonukleotide der c-klasse

Info

Publication number: ATE527355T1
Authority: AT; Austria
Prior art keywords: stimulative; immuno; oligonucleotides; soft; class semi
Prior art date: 2004-10-20

Application number

AT05858251T

Other languages

English (en)

Inventor

Arthur Krieg

Ulrike Samulowitz

Jorg Vollmer

Eugen Uhlmann

Original Assignee

Coley Pharm Group Inc

Coley Pharm Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-20

Filing date

2005-10-20

Publication date

2011-10-15

2005-10-20 Application filed by Coley Pharm Group Inc, Coley Pharm Gmbh filed Critical Coley Pharm Group Inc

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE527355T1 publication Critical patent/ATE527355T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
230000003308 immunostimulating effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Otolaryngology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT05858251T 2004-10-20 2005-10-20 Halbweiche immunstimulierende oligonukleotide der c-klasse ATE527355T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US62075904P	2004-10-20	2004-10-20
PCT/US2005/037731 WO2006135434A2 (en)	2004-10-20	2005-10-20	Semi-soft c-class immunostimulatory oligonucleotides

Publications (1)

Publication Number	Publication Date
ATE527355T1 true ATE527355T1 (de)	2011-10-15

Family

ID=37507656

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05858251T ATE527355T1 (de)	2004-10-20	2005-10-20	Halbweiche immunstimulierende oligonukleotide der c-klasse

Country Status (28)

Country	Link
US (3)	US7566703B2 (de)
EP (1)	EP1802757B1 (de)
JP (1)	JP2008516634A (de)
KR (1)	KR20070065392A (de)
CN (1)	CN101084310A (de)
AR (1)	AR051462A1 (de)
AT (1)	ATE527355T1 (de)
AU (1)	AU2005332970A1 (de)
BR (1)	BRPI0516497A (de)
CA (1)	CA2578844A1 (de)
CR (1)	CR9131A (de)
ES (1)	ES2375071T3 (de)
GT (1)	GT200500294A (de)
IL (1)	IL182470A0 (de)
MA (1)	MA29028B1 (de)
MY (1)	MY159370A (de)
NO (1)	NO20072526L (de)
NZ (1)	NZ554753A (de)
PA (1)	PA8650101A1 (de)
PE (1)	PE20061045A1 (de)
RS (1)	RS20070164A (de)
RU (1)	RU2393223C2 (de)
SV (1)	SV2006002279A (de)
TN (1)	TNSN07150A1 (de)
TW (1)	TW200626720A (de)
UY (1)	UY29173A1 (de)
WO (1)	WO2006135434A2 (de)
ZA (2)	ZA200703609B (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030109469A1 (en) *	1993-08-26	2003-06-12	Carson Dennis A.	Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US7935675B1 (en) *	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
EP0855184A1 (de) *	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU760795B2 (en) *	1998-05-14	2003-05-22	Coley Pharmaceutical Gmbh	Methods for regulating hematopoiesis using CpG-oligonucleotides
DK1077722T3 (da)	1998-05-22	2006-11-27	Ottawa Health Research Inst	Fremgangsmåder og produkter til induktion af mukosaimmunitet
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
DE60044236D1 (de) *	1999-02-17	2010-06-02	Csl Ltd	Immunogene komplexe und methoden in bezug auf diese
US6949520B1 (en) *	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
EP1296714B1 (de) *	2000-06-22	2009-08-26	University Of Iowa Research Foundation	Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
EA007232B1 (ru)	2001-08-17	2006-08-25	Коли Фармасьютикал Гмбх	Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
US7276489B2 (en) *	2002-10-24	2007-10-02	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
NZ535952A (en)	2002-04-04	2009-01-31	Coley Pharm Gmbh	Immunostimulatory G,U-containing oligoribonucleotides
US7605138B2 (en)	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) *	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en)	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
NZ540098A (en) *	2002-10-29	2008-09-26	Coley Pharmaceutical Group Ltd	Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7956043B2 (en)	2002-12-11	2011-06-07	Coley Pharmaceutical Group, Inc.	5′ CpG nucleic acids and methods of use
EP1608403A2 (de) *	2003-04-02	2005-12-28	Coley Pharmaceutical Group, Ltd.	Immunostimulatorische nukleinsäure öl-in-wasser emulsionen zur topischen anwendung
US7410975B2 (en) *	2003-06-20	2008-08-12	Coley Pharmaceutical Group, Inc.	Small molecule toll-like receptor (TLR) antagonists
JP4989225B2 (ja) *	2003-09-25	2012-08-01	コーリーファーマシューティカルグループ，インコーポレイテッド	核酸親油性接合体
NZ546275A (en)	2003-10-30	2009-05-31	Coley Pharm Gmbh	C-class oligonucleotides analogs with enhanced immunostimulatory potency
US20050239733A1 (en) *	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
JP2007526253A (ja) *	2004-02-19	2007-09-13	コーリーファーマシューティカルグループ，インコーポレイテッド	免疫刺激性ウイルスｒｎａオリゴヌクレオチド
JP2007531746A (ja) *	2004-04-02	2007-11-08	コーリーファーマシューティカルグループ，インコーポレイテッド	Ｉｌ−１０応答を誘導するための免疫活性化核酸
JP2008506789A (ja) *	2004-07-18	2008-03-06	シーエスエル、リミテッド	インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
MY159370A (en)	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
KR20070110901A (ko)	2005-03-04	2007-11-20	다이나박스 테크놀로지 코퍼레이션	항원에 콘쥬게이트되고 버퍼 조건 및 추가의 부형제들에의해 안정화된 면역자극성 서열(ｉｓｓ)을 갖는올리고뉴클레오티드를 포함하는 백신
US20060213010A1 (en) *	2005-03-22	2006-09-28	Davis David T	Mattress sled
EP1874325A2 (de) *	2005-04-08	2008-01-09	Coley Pharmaceutical Group, Inc.	Verfahren zur behandlung von durch infektionserkrankungen verschlimmertes asthma
WO2007008463A2 (en) *	2005-07-07	2007-01-18	Coley Pharmaceutical Group, Inc.	Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
KR20080047463A (ko) *	2005-09-16	2008-05-28	콜리 파마슈티칼 게엠베하	뉴클레오티드 변형에 의한 짧은 간섭 리보핵산(ｓｉｒｎａ)의 면역자극 특성의 조절
US20090214578A1 (en) *	2005-09-16	2009-08-27	Coley Pharmaceutical Gmbh	Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone
WO2007062107A2 (en)	2005-11-25	2007-05-31	Coley Pharmaceutical Gmbh	Immunostimulatory oligoribonucleotides
WO2007095316A2 (en) *	2006-02-15	2007-08-23	Coley Pharmaceutical Gmbh	Compositions and methods for oligonucleotide formulations
MX2009003398A (es)	2006-09-27	2009-08-12	Coley Pharm Gmbh	Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
US20090142362A1 (en) *	2006-11-06	2009-06-04	Avant Immunotherapeutics, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
US8309529B2 (en)	2007-05-04	2012-11-13	Index Pharmaceuticals Ab	Tumour growth inhibitory compounds and methods of their use
KR20100045508A (ko)	2007-08-13	2010-05-03	콜리 파마슈티칼 게엠베하	특이적 면역 조절 프로필을 유도하는 규정된 뉴클레오티드간 연결의 환경에서의 ｒｎａ 서열 모티프
EP2278979A4 (de)	2008-05-21	2012-09-26	Us Gov Health & Human Serv	Verfahren zur behandlung von pneumokoniose mit oligodesoxynukleotiden
US20110182880A1 (en) *	2008-06-18	2011-07-28	Oliver Von Stein	Combination Therapies Against Cancer
US20110280934A1 (en) *	2008-11-04	2011-11-17	Asa Karlsson	Increased Expression of Specific Antigens
US8053422B2 (en)	2008-12-04	2011-11-08	The United States Of America As Represented By The Department Of Health And Human Services	Anti-cancer oligodeoxynucleotides
KR101329374B1 (ko)	2008-12-09	2013-11-14	콜레이 파마시티컬 그룹, 인코포레이티드	면역자극성 올리고뉴클레오타이드
KR101856462B1 (ko)	2009-03-25	2018-05-10	보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	병원체에 대한 포유동물의 선천성 면역 저항성의 자극을 위한 조성물
CN107617110A (zh)	2009-08-26	2018-01-23	西莱克塔生物科技公司	诱导t细胞辅助的组合物
CA2782366A1 (en) *	2009-12-16	2011-07-14	Opko Curna, Llc	Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
CN107029223A (zh)	2010-05-26	2017-08-11	西莱克塔生物科技公司	合成纳米载体联合疫苗
EP2640190A4 (de)	2010-11-05	2016-05-11	Selecta Biosciences Inc	Modifizierte nikotinische verbindungen und zugehörige verfahren
JP2014521687A (ja)	2011-07-29	2014-08-28	セレクタバイオサイエンシーズインコーポレーテッド	体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
EP2968510B1 (de)	2013-03-14	2019-10-09	President and Fellows of Harvard College	Zusammensetzungen von nanopartikeln
CA2919268C (en)	2013-07-25	2023-09-05	Exicure, Inc.	Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015130584A2 (en)	2014-02-25	2015-09-03	Merck Sharp & Dohme Corp.	Lipid nanoparticle vaccine adjuvants and antigen delivery systems
AU2015269412B2 (en)	2014-06-04	2020-03-12	Exicure Operating Company	Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3160453A1 (de)	2014-06-25	2017-05-03	Selecta Biosciences, Inc.	Verfahren und zusammensetzungen zur behandlung mit synthetischen nanoträgern und immun-checkpoint-hemmern
WO2016044839A2 (en)	2014-09-19	2016-03-24	The Board Of Regents Of The University Of Texas System	Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2016081911A2 (en)	2014-11-21	2016-05-26	Northwestern University	The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
HUE053145T2 (hu)	2014-12-31	2021-06-28	Checkmate Pharmaceuticals Inc	Kombinált tumor immunterápia
EP3302501B1 (de)	2015-05-29	2021-09-22	Merck Sharp & Dohme Corp.	Kombination aus einem pd-1-antagonisten und cpg-c-typ-oligonukleotid zur behandlung von krebs
EP3301179B1 (de)	2015-07-09	2019-06-05	National Institute for Materials Science	Immunstimulierender oligonukleotidkomplex
DK3325015T3 (da) *	2015-07-20	2021-07-05	Zoetis Services Llc	Liposomale adjuvanssammensætninger
US10456459B2 (en) *	2015-07-20	2019-10-29	Zoetis Services Llc	Liposomal adjuvant compositions
US20190046638A1 (en)	2016-04-01	2019-02-14	Checkmate Pharmaceuticals, Inc.	Fc RECEPTOR-MEDIATED DRUG DELIVERY
WO2018039629A2 (en)	2016-08-25	2018-03-01	Northwestern University	Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018077385A1 (en) *	2016-10-25	2018-05-03	Biontech Rna Pharmaceuticals Gmbh	Dose determination for immunotherapeutic agents
US12460208B2 (en)	2017-04-18	2025-11-04	Parr Biotechnology Co., Ltd.	Immunomodulatory polynucleotides and uses thereof
CN108728444A (zh) *	2017-04-18	2018-11-02	长春华普生物技术股份有限公司	免疫调节性多核苷酸及其应用
WO2018201090A1 (en)	2017-04-28	2018-11-01	Exicure, Inc.	Synthesis of spherical nucleic acids using lipophilic moieties
WO2019160866A2 (en)	2018-02-13	2019-08-22	Checkmate Pharmaceuticals, Inc.	Compositions and methods for tumor immunotherapy
BR112020020479A2 (pt)	2018-04-09	2021-01-12	Checkmate Pharmaceuticals	Empacotamento de oligonucleotídeos em partículas similares a vírus

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5194428A (en)	1986-05-23	1993-03-16	Worcester Foundation For Experimental Biology	Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US4806463A (en)	1986-05-23	1989-02-21	Worcester Foundation For Experimental Biology	Inhibition of HTLV-III by exogenous oligonucleotides
US5276019A (en)	1987-03-25	1994-01-04	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en)	1987-03-25	1993-11-23	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5004810A (en)	1988-09-30	1991-04-02	Schering Corporation	Antiviral oligomers
US5399676A (en)	1989-10-23	1995-03-21	Gilead Sciences	Oligonucleotides with inverted polarity
US5177198A (en)	1989-11-30	1993-01-05	University Of N.C. At Chapel Hill	Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5587361A (en)	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5514788A (en)	1993-05-17	1996-05-07	Isis Pharmaceuticals, Inc.	Oligonucleotide modulation of cell adhesion
US5166195A (en)	1990-05-11	1992-11-24	Isis Pharmaceuticals, Inc.	Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
ATE318832T1 (de)	1990-06-11	2006-03-15	Gilead Sciences Inc	Verfahren zur vervendung von nukleinsäureliganden
EP0468520A3 (en)	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
US6605708B1 (en)	1993-07-28	2003-08-12	Hybridon, Inc.	Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom
US5859231A (en)	1993-09-03	1999-01-12	Duke University	Synthesis of oligonucleotides with boranophosphonate linkages
DE4338704A1 (de)	1993-11-12	1995-05-18	Hoechst Ag	Stabilisierte Oligonucleotide und deren Verwendung
US5596091A (en)	1994-03-18	1997-01-21	The Regents Of The University Of California	Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6727230B1 (en)	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
MY114769A (en) *	1994-04-18	2003-01-31	Aviron Inc	Non-splicing variants of gp350/220
US5696248A (en)	1994-06-15	1997-12-09	Hoechst Aktiengesellschaft	3'-modified oligonucleotide derivatives
US20030050263A1 (en)	1994-07-15	2003-03-13	The University Of Iowa Research Foundation	Methods and products for treating HIV infection
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
AU713040B2 (en)	1994-07-15	1999-11-18	University Of Iowa Research Foundation, The	Immunomodulatory oligonucleotides
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6160109A (en)	1995-10-20	2000-12-12	Isis Pharmaceuticals, Inc.	Preparation of phosphorothioate and boranophosphate oligomers
EP0855184A1 (de)	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
CA2281838A1 (en)	1997-02-28	1998-09-03	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en)	1997-04-30	2002-07-30	Hybridon, Inc.	Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
EP1003531B1 (de)	1997-05-20	2007-08-22	Ottawa Health Research Institute	Verfahren zur Herstellung von Nukleinsäurekonstrukten
US6589940B1 (en)	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en)	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
ATE408422T1 (de)	1997-07-03	2008-10-15	Donald E Macfarlane	Methode zur hemmung immunstimulatorischer mit dna assoziierter antworten
PT1009413E (pt)	1997-09-05	2007-05-31	Univ California	Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
US6218371B1 (en)	1998-04-03	2001-04-17	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP1077708A1 (de)	1998-05-06	2001-02-28	University Of Iowa Research Foundation	Methoden zur preventiven und therapeutischen behandlung von parasitären infektionen und damit verbundener krankheiten mittels cpg oligonukleotiden
AU760795B2 (en)	1998-05-14	2003-05-22	Coley Pharmaceutical Gmbh	Methods for regulating hematopoiesis using CpG-oligonucleotides
DK1077722T3 (da)	1998-05-22	2006-11-27	Ottawa Health Research Inst	Fremgangsmåder og produkter til induktion af mukosaimmunitet
JP2002521489A (ja)	1998-07-27	2002-07-16	ユニバーシティオブアイオワリサーチファウンデーション	ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法
WO2000014217A2 (en)	1998-09-03	2000-03-16	Coley Pharmaceutical Gmbh	G-motif oligonucleotides and uses thereof
US6207819B1 (en)	1999-02-12	2001-03-27	Isis Pharmaceuticals, Inc.	Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
FR2790955B1 (fr) *	1999-03-19	2003-01-17	Assist Publ Hopitaux De Paris	Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
EP1177439B1 (de)	1999-04-29	2004-09-08	Coley Pharmaceutical GmbH	Screening nach modulatoren der funktion von immunstimulatorischer dna
AP1891A (en)	1999-05-06	2008-09-23	The Immune Response Corp	HIV immunogenic compositions and methods.
CA2412345A1 (en)	1999-06-16	2000-12-21	University Of Iowa Research Foundation	Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
US6514948B1 (en)	1999-07-02	2003-02-04	The Regents Of The University Of California	Method for enhancing an immune response
WO2001022972A2 (en)	1999-09-25	2001-04-05	University Of Iowa Research Foundation	Immunostimulatory nucleic acids
US6949520B1 (en) *	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
WO2001051500A1 (en) *	2000-01-14	2001-07-19	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
US20010044416A1 (en)	2000-01-20	2001-11-22	Mccluskie Michael J.	Immunostimulatory nucleic acids for inducing a Th2 immune response
WO2001055370A2 (en)	2000-01-26	2001-08-02	Hybridon, Inc.	MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20020156033A1 (en)	2000-03-03	2002-10-24	Bratzler Robert L.	Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en)	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
EP1296714B1 (de)	2000-06-22	2009-08-26	University Of Iowa Research Foundation	Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
US20020165178A1 (en)	2000-06-28	2002-11-07	Christian Schetter	Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
US20020198165A1 (en)	2000-08-01	2002-12-26	Bratzler Robert L.	Nucleic acids for the prevention and treatment of gastric ulcers
US20020091097A1 (en)	2000-09-07	2002-07-11	Bratzler Robert L.	Nucleic acids for the prevention and treatment of sexually transmitted diseases
EP1366077B1 (de) *	2000-09-15	2011-05-25	Coley Pharmaceutical GmbH	Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten
EP2292632A3 (de)	2000-09-26	2012-07-25	Idera Pharmaceuticals, Inc.	Modulation der immunostimulatorischen Aktivität von immunostimulierenden Oligonukleotidanaloga durch positionelle chemische Veränderungen
WO2002069369A2 (en)	2000-12-08	2002-09-06	Coley Pharmaceutical Gmbh	Cpg-like nucleic acids and methods of use thereof
AU2002248185A1 (en)	2000-12-14	2002-07-16	Coley Pharmaceutical Group, Inc.	Inhibition of angiogenesis by nucleic acids
EP1364010B1 (de)	2000-12-27	2010-06-16	Dynavax Technologies Corporation	Immunomodulatorische polynukleotide und verfahren zur deren verwendung
US20030050268A1 (en)	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US7105495B2 (en)	2001-04-30	2006-09-12	Idera Pharmaceuticals, Inc.	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US20030129605A1 (en)	2001-05-04	2003-07-10	Dong Yu	Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosophonate linkages
US20040132677A1 (en)	2001-06-21	2004-07-08	Fearon Karen L.	Chimeric immunomodulatory compounds and methods of using the same-IV
KR100985457B1 (ko)	2001-06-21	2010-10-06	다이나박스 테크놀로지 코퍼레이션	키메라 면역조절 화합물 및 그것들의 사용 방법
US20030003970A1 (en)	2001-06-28	2003-01-02	Alan Johnson	Portable communications device
AU2002318944A1 (en)	2001-08-01	2003-02-17	Coley Pharmaceutical Gmbh	Methods and compositions relating to plasmacytoid dendritic cells
EA007232B1 (ru)	2001-08-17	2006-08-25	Коли Фармасьютикал Гмбх	Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
WO2004012669A2 (en) *	2002-08-01	2004-02-12	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
WO2003031573A2 (en)	2001-10-05	2003-04-17	Coley Pharmaceutical Gmbh	Toll-like receptor 3 signaling agonists and antagonists
AU2002360278A1 (en)	2001-10-12	2003-11-11	Coley Pharmaceutical Gmbh	Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2003035836A2 (en) *	2001-10-24	2003-05-01	Hybridon Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US7276489B2 (en)	2002-10-24	2007-10-02	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
JP4000251B2 (ja) *	2001-10-31	2007-10-31	富士通株式会社	光信号交換装置およびその制御方法
AU2002366710A1 (en) *	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US20030232443A1 (en)	2002-06-18	2003-12-18	Isis Pharmaceuticals Inc.	Antisense modulation of centromere protein B expression
NZ535952A (en)	2002-04-04	2009-01-31	Coley Pharm Gmbh	Immunostimulatory G,U-containing oligoribonucleotides
CN101160399A (zh)	2002-04-22	2008-04-09	拜奥尼茨生命科学公司	寡核苷酸组合物及其在调节免疫应答中的应用
WO2003103586A2 (en)	2002-06-05	2003-12-18	Coley Pharmaceutical Group, Inc.	Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
US7576066B2 (en)	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
SG167667A1 (en)	2002-07-03	2011-01-28	Coley Pharm Group Inc	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) *	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en)	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
WO2004007743A2 (en)	2002-07-17	2004-01-22	Coley Pharmaceutical Gmbh	Use of cpg nucleic acids in prion-disease
AR040996A1 (es) *	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
AU2003278845A1 (en)	2002-09-19	2004-04-08	Coley Pharmaceutical Gmbh	Toll-like receptor 9 (tlr9) from various mammalian species
NZ540098A (en) *	2002-10-29	2008-09-26	Coley Pharmaceutical Group Ltd	Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7956043B2 (en) *	2002-12-11	2011-06-07	Coley Pharmaceutical Group, Inc.	5′ CpG nucleic acids and methods of use
DK1992635T3 (da)	2002-12-23	2012-03-05	Dynavax Tech Corp	Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
US7625872B2 (en)	2002-12-23	2009-12-01	Dynavax Technologies Corporation	Branched immunomodulatory compounds and methods of using the same
JP4726630B2 (ja)	2003-01-16	2011-07-20	イデラファーマシューティカルズインコーポレイテッド	修飾された免疫賦活性ジヌクレオチドを用いることによるオリゴヌクレオチドに基づく化合物の免疫賦活特性の調節
EP1608403A2 (de) *	2003-04-02	2005-12-28	Coley Pharmaceutical Group, Ltd.	Immunostimulatorische nukleinsäure öl-in-wasser emulsionen zur topischen anwendung
WO2004094671A2 (en)	2003-04-22	2004-11-04	Coley Pharmaceutical Gmbh	Methods and products for identification and assessment of tlr ligands
JP4874801B2 (ja) *	2003-06-11	2012-02-15	イデラファーマシューティカルズインコーポレイテッド	安定化免疫調節オリゴヌクレオチド
US7410975B2 (en)	2003-06-20	2008-08-12	Coley Pharmaceutical Group, Inc.	Small molecule toll-like receptor (TLR) antagonists
MXPA06000619A (es)	2003-07-15	2006-04-11	Hybridon Inc	Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
JP4989225B2 (ja)	2003-09-25	2012-08-01	コーリーファーマシューティカルグループ，インコーポレイテッド	核酸親油性接合体
US20050215501A1 (en) *	2003-10-24	2005-09-29	Coley Pharmaceutical Group, Inc.	Methods and products for enhancing epitope spreading
NZ546275A (en)	2003-10-30	2009-05-31	Coley Pharm Gmbh	C-class oligonucleotides analogs with enhanced immunostimulatory potency
US20050239733A1 (en)	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en)	2003-11-06	2005-05-12	Coley Pharmaceutical Gmbh	Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
KR101138131B1 (ko)	2003-12-08	2012-04-23	이데라 파마슈티칼즈, 인코포레이티드	작은 올리고뉴클레오티드-기초 화합물에 의한 면역자극특성의 조절
JP2007526253A (ja)	2004-02-19	2007-09-13	コーリーファーマシューティカルグループ，インコーポレイテッド	免疫刺激性ウイルスｒｎａオリゴヌクレオチド
US7668561B2 (en) *	2004-02-27	2010-02-23	Qualcomm Incorporated	Apparatus and method for controlling reverse link interference among access terminals in wireless communications
CA2557443A1 (en)	2004-03-12	2005-09-29	Hybridon, Inc.	Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
JP2007531746A (ja)	2004-04-02	2007-11-08	コーリーファーマシューティカルグループ，インコーポレイテッド	Ｉｌ−１０応答を誘導するための免疫活性化核酸
WO2006080946A2 (en)	2004-06-08	2006-08-03	Coley Pharmaceutical Gmbh	Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
BRPI0512110A (pt)	2004-06-15	2007-10-23	Idera Pharmaceutical Inc	multìmeros de oligonucleotìdeos imunoestimulatórios
JP2008506789A (ja) *	2004-07-18	2008-03-06	シーエスエル、リミテッド	インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
EP1776105A2 (de) *	2004-07-18	2007-04-25	Coley Pharmaceutical Group, Ltd	Verfahren und zusammensetzungen zur induzierung eigener immunantworten
MY159370A (en) *	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
CN101119768A (zh) *	2005-01-12	2008-02-06	安姆科尔国际公司	含有用胶体阳离子颗粒预乳化的疏水有益试剂的洗涤组合物
WO2006091915A2 (en)	2005-02-24	2006-08-31	Coley Pharmaceutical Group, Inc.	Immunostimulatory oligonucleotides
EP1874325A2 (de) *	2005-04-08	2008-01-09	Coley Pharmaceutical Group, Inc.	Verfahren zur behandlung von durch infektionserkrankungen verschlimmertes asthma
AU2006241149A1 (en)	2005-04-26	2006-11-02	Coley Pharmaceutical Gmbh	Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
US20070093439A1 (en)	2005-10-25	2007-04-26	Idera Pharmaceuticals, Inc.	Short immunomodulatory oligonucleotides
WO2007062107A2 (en)	2005-11-25	2007-05-31	Coley Pharmaceutical Gmbh	Immunostimulatory oligoribonucleotides
WO2007095316A2 (en) *	2006-02-15	2007-08-23	Coley Pharmaceutical Gmbh	Compositions and methods for oligonucleotide formulations
US8027888B2 (en)	2006-08-31	2011-09-27	Experian Interactive Innovation Center, Llc	Online credit card prescreen systems and methods
WO2008033432A2 (en)	2006-09-12	2008-03-20	Coley Pharmaceutical Group, Inc.	Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
MX2009003398A (es)	2006-09-27	2009-08-12	Coley Pharm Gmbh	Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
US20100189772A1 (en)	2006-09-27	2010-07-29	Coley Pharmaceutical Group, Inc	Compositions of TLR ligands and antivirals
EP2104738A2 (de)	2006-10-26	2009-09-30	Coley Pharmaceuticals GmbH	Oligoribonukleotide und ihre verwendung
US20090142362A1 (en) *	2006-11-06	2009-06-04	Avant Immunotherapeutics, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
CN101820908A (zh) *	2007-10-09	2010-09-01	科利制药公司	包含改性糖部分的免疫刺激寡核苷酸类似物

2005
- 2005-10-18 MY MYPI20054890A patent/MY159370A/en unknown
- 2005-10-19 GT GT200500294A patent/GT200500294A/es unknown
- 2005-10-19 UY UY29173A patent/UY29173A1/es not_active Application Discontinuation
- 2005-10-19 AR ARP050104368A patent/AR051462A1/es unknown
- 2005-10-19 TW TW094136646A patent/TW200626720A/zh unknown
- 2005-10-20 AU AU2005332970A patent/AU2005332970A1/en not_active Abandoned
- 2005-10-20 RU RU2007118681/13A patent/RU2393223C2/ru not_active IP Right Cessation
- 2005-10-20 CA CA002578844A patent/CA2578844A1/en not_active Abandoned
- 2005-10-20 ZA ZA200703609A patent/ZA200703609B/xx unknown
- 2005-10-20 RS RSP-2007/0164A patent/RS20070164A/sr unknown
- 2005-10-20 KR KR1020077008882A patent/KR20070065392A/ko not_active Withdrawn
- 2005-10-20 CN CNA2005800436842A patent/CN101084310A/zh active Pending
- 2005-10-20 BR BRPI0516497-4A patent/BRPI0516497A/pt not_active Application Discontinuation
- 2005-10-20 SV SV2005002279A patent/SV2006002279A/es unknown
- 2005-10-20 WO PCT/US2005/037731 patent/WO2006135434A2/en not_active Ceased
- 2005-10-20 US US11/255,100 patent/US7566703B2/en not_active Expired - Fee Related
- 2005-10-20 PE PE2005001231A patent/PE20061045A1/es not_active Application Discontinuation
- 2005-10-20 EP EP05858251A patent/EP1802757B1/de not_active Expired - Lifetime
- 2005-10-20 JP JP2007538026A patent/JP2008516634A/ja not_active Withdrawn
- 2005-10-20 ES ES05858251T patent/ES2375071T3/es not_active Expired - Lifetime
- 2005-10-20 NZ NZ554753A patent/NZ554753A/en not_active IP Right Cessation
- 2005-10-20 AT AT05858251T patent/ATE527355T1/de not_active IP Right Cessation
- 2005-10-20 PA PA20058650101A patent/PA8650101A1/es unknown
2007
- 2007-04-11 IL IL182470A patent/IL182470A0/en unknown
- 2007-04-19 TN TNP2007000150A patent/TNSN07150A1/fr unknown
- 2007-05-16 NO NO20072526A patent/NO20072526L/no not_active Application Discontinuation
- 2007-05-17 MA MA29915A patent/MA29028B1/fr unknown
- 2007-05-18 CR CR9131A patent/CR9131A/es not_active Application Discontinuation
2008
- 2008-04-30 ZA ZA200803752A patent/ZA200803752B/xx unknown
- 2008-12-17 US US12/336,986 patent/US7795235B2/en not_active Expired - Fee Related
2010
- 2010-09-14 US US12/881,475 patent/US20110201672A1/en not_active Abandoned

Also Published As

Publication number	Publication date
RU2393223C2 (ru)	2010-06-27
EP1802757A2 (de)	2007-07-04
GT200500294A (es)	2006-04-05
MA29028B1 (fr)	2007-11-01
CN101084310A (zh)	2007-12-05
TNSN07150A1 (en)	2008-11-21
US7566703B2 (en)	2009-07-28
RU2007118681A (ru)	2008-11-27
EP1802757B1 (de)	2011-10-05
CR9131A (es)	2007-10-22
RS20070164A (sr)	2009-01-22
WO2006135434A3 (en)	2007-05-10
AU2005332970A1 (en)	2006-12-21
TW200626720A (en)	2006-08-01
CA2578844A1 (en)	2006-12-21
PA8650101A1 (es)	2006-08-03
US20090137519A1 (en)	2009-05-28
WO2006135434A2 (en)	2006-12-21
NZ554753A (en)	2010-03-26
US7795235B2 (en)	2010-09-14
ES2375071T3 (es)	2012-02-24
KR20070065392A (ko)	2007-06-22
AR051462A1 (es)	2007-01-17
JP2008516634A (ja)	2008-05-22
IL182470A0 (en)	2007-09-20
SV2006002279A (es)	2006-07-07
NO20072526L (no)	2007-07-20
UY29173A1 (es)	2006-05-31
US20110201672A1 (en)	2011-08-18
ZA200703609B (en)	2008-10-29
BRPI0516497A (pt)	2008-09-09
ZA200803752B (en)	2010-03-31
PE20061045A1 (es)	2006-11-07
MY159370A (en)	2016-12-30
US20060140875A1 (en)	2006-06-29

Legal Events

Date	Code	Title	Description
2012-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE602005022897D1 (de)	2010-09-23	Piperidinylamino-thienoä2,3-dü-pyrimidinverbindungen
EP1791567A4 (de)	2009-12-23	Chemisch modifizierte oligonucleotide
ATE469145T1 (de)	2010-06-15	4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
NL1028967A1 (nl)	2005-11-08	4-Fenylamino-chinazoline-6-yl-amiden.
NO20051522D0 (no)	2005-03-22	Kabelskjotbeskytter.
FR2871075B1 (fr)	2015-09-11	Catalyseur
DE602007001681D1 (de)	2009-09-03	1,3-dioxan-carboxylsäuren
FI20041113A0 (fi)	2004-08-25	Aksiaalivuoinduktiosähkökone
NO20053210D0 (no)	2005-06-30	Linneslakkompensator.
ATE459633T1 (de)	2010-03-15	Makrolide
NO20041374L (no)	2005-10-03	Bolgekraftverk.
NO20040762D0 (no)	2004-02-20	Stromskinne.
DE502004006772D1 (de)	2008-05-21	Wirkwerkzeug-Barre
DK1907574T3 (da)	2014-01-20	Oligonukleotider
NO20052746D0 (no)	2005-06-08	Avlopsenhet.
DE602005012919D1 (de)	2009-04-09	Brillenendstück
NO20052482D0 (no)	2005-05-23	Redningskokong.
AT500198B1 (de)	2006-09-15	Ladewagen
ATE389633T1 (de)	2008-04-15	Omega-phenyloctanamide
DE602005026899D1 (de)	2011-04-28	Bildaufzeichungselement
AT500249A3 (de)	2006-03-15	Scheibenegge
NL1028622A1 (nl)	2005-09-27	Stelwig.
NL1025196A1 (nl)	2004-02-24	Hark-Zeef-Vork.
FR2867906B1 (fr)	2006-06-02	Repartiteur
ES1057865Y (es)	2005-01-16	Desatascador de desagues.